Altimmune Announces Notice of Allowance on Patent Covering Use of NasoShield in the U.S.

Altimmune (Nasdaq:ALT) a clinical-stage immunotherapeutics company, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (US PTO) for patent application No. 14/870,570, “Targets and Compositions for Use in Decontamination, Immunoprophylaxis, and Post-Exposure Therapy Against Anthrax” (‘570 patent).
As quoted in the press release:

“We continue to protect our technology through strategic intellectual property achievements and this Notice of Allowance is an important addition to our IP portfolio,” said Bill Enright, President and Chief Executive Officer of Altimmune.

Click here to read the full press release.